Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
complement C5 inhibitor
Description:
A complement C5 inhibitor is a drug or agent that blocks C5 activation in the immune complement cascade.
Primary topic:
Complement system in diseases (53%)
Related topics:
Complement system in diseases (53%),
Myasthenia Gravis and Thymoma (21%),
Multiple Sclerosis Research Studies (9%)
OpenAlex ID:
keywords/complement-c5-inhibitor
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
2018
·
Jong Wook Lee
, Flore Sicre de Fontbrune
, et al.
·
Blood
·
497
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
2023
·
James F Howard
, Saskia Bresch
, et al.
·
The Lancet Neurology
·
324
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
2015
·
Richard J. Kelly
, Britta Höchsmann
, et al.
·
New England Journal of Medicine
·
315
PDF
Ravulizumab: First Global Approval
2019
·
Kate McKeage
·
Drugs
·
135
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
2018
·
Kioa L. Wijnsma
, Caroline Duineveld
, et al.
·
Pediatric Nephrology
·
126
PDF
Novel Treatments in Myasthenia Gravis
2020
·
Deepak Menon
, Carolina Barnett
, et al.
·
Frontiers in Neurology
·
120
PDF
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
2020
·
Gema Ariceta
, Bradley P. Dixon
, et al.
·
Kidney International
·
111
PDF
Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
2015
·
Lars Pape
, Hans Hartmann
, et al.
·
Medicine
·
110
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial
2024
·
Richard Lafayette
, James Tumlin
, et al.
·
Journal of the American Society of Nephrology
·
97
Avacincaptad Pegol: First Approval
2023
·
Connie Kang
·
Drugs
·
95
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
2019
·
Robert M. Stern
, Nathan T. Connell
·
Therapeutic Advances in Hematology
·
92
PDF
A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA
2023
·
Sonata Jodele
, Christopher E. Dandoy
, et al.
·
Blood
·
77
PDF
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies
2022
·
Austin G. Kulasekararaj
, Morag Griffin
, et al.
·
European Journal Of Haematology
·
76
PDF
Therapy of scleroderma renal crisis: State of the art
2018
·
Elisabetta Zanatta
, Pamela Polito
, et al.
·
Autoimmunity Reviews
·
75
Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
2021
·
Fadi Fakhouri
, Marie Scully
, et al.
·
Journal of Nephrology
·
74
PDF
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial
2023
·
Andrew L Mammen
, Anthony A Amato
, et al.
·
The Lancet Rheumatology
·
72
PDF
Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients
2020
·
Jeroen D. Langereis
, Bryan van den Broek
, et al.
·
Blood Advances
·
52
Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment
2022
·
Urszula Szlendak
, Bożena Budziszewska
, et al.
·
Polskie Archiwum Medycyny Wewnętrznej
·
49
PDF
Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans
2011
·
Andreas Barratt-Due
, Ebbe Billmann Thorgersen
, et al.
·
The Journal of Immunology
·
49
PDF
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH ( COMMODORE 3): A multicenter, Phase 3, single‐arm study
2023
·
Hui Liu
, Linghui Xia
, et al.
·
American Journal of Hematology
·
47
PDF
Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand
2018
·
Lucy C Fox
, Solomon J Cohney
, et al.
·
Nephrology
·
46
PDF
Zilucoplan: First Approval
2023
·
Matt Shirley
·
Drugs
·
45
PDF
C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review
2024
·
Carl J Danzig
, Arshad M Khanani
, et al.
·
Immunotherapy
·
42
Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT
2022
·
Kana Mizuno
, Christopher E. Dandoy
, et al.
·
Blood Advances
·
42
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study
2020
·
Hubert Schrezenmeier
, Austin Kulasekararaj
, et al.
·
Therapeutic Advances in Hematology
·
42
PDF
Show more works
View as search
Works count:
328
Citation count:
3,902
Year
Topic
Type